300146 汤臣倍健
交易中 06-29 10:34:27
资讯
新帖
简况
6月26日汤臣倍健创60日新低，体育LOF基金重仓该股
证券之星 · 06-26 16:55
6月26日汤臣倍健创60日新低，体育LOF基金重仓该股
汤臣倍健(300146.SZ)拟5000万元投资原粒(北京)半导体 将持有其0.97%的股权
智通财经 · 06-18
汤臣倍健(300146.SZ)拟5000万元投资原粒(北京)半导体 将持有其0.97%的股权
股市必读：汤臣倍健（300146）5月26日董秘有最新回复
证券之星 · 05-27
股市必读：汤臣倍健（300146）5月26日董秘有最新回复
股市必读：汤臣倍健（300146）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：汤臣倍健（300146）5月22日董秘有最新回复
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
证券之星 · 05-22
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
5月22日汤臣倍健创60日新低，体育LOF基金重仓该股
证券之星 · 05-22
5月22日汤臣倍健创60日新低，体育LOF基金重仓该股
股市必读：汤臣倍健（300146）5月20日董秘有最新回复
证券之星 · 05-21
股市必读：汤臣倍健（300146）5月20日董秘有最新回复
汤臣倍健：公司始终聚焦主业，致力于实现可持续、有质量发展
证券之星 · 05-20
汤臣倍健：公司始终聚焦主业，致力于实现可持续、有质量发展
股市必读：汤臣倍健（300146）5月18日董秘有最新回复
证券之星 · 05-19
股市必读：汤臣倍健（300146）5月18日董秘有最新回复
汤臣倍健：保健食品不适用上述法规
证券之星 · 05-18
汤臣倍健：保健食品不适用上述法规
汤臣倍健：公司目前未投资DeepSeek
证券之星 · 05-15
汤臣倍健：公司目前未投资DeepSeek
东吴证券：给予汤臣倍健买入评级
证券之星 · 05-12
东吴证券：给予汤臣倍健买入评级
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
证券之星 · 05-11
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
证券之星 · 05-07
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累
证券之星 · 05-07
汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累
汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略
证券之星 · 04-28
汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略
汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%
证券之星 · 04-25
汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%
汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%
智通财经 · 04-24
汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%
股市必读：汤臣倍健（300146）4月22日董秘有最新回复
证券之星 · 04-23
股市必读：汤臣倍健（300146）4月22日董秘有最新回复
汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交
证券之星 · 04-22
汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交
加载更多
公司概况
公司名称：
汤臣倍健股份有限公司
所属行业：
食品制造业
上市日期：
2010-12-15
主营业务：
汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。
发行价格：
110.00
{"stockData":{"symbol":"300146","market":"SZ","secType":"STK","nameCN":"汤臣倍健","latestPrice":9.38,"timestamp":1782700467000,"preClose":9.24,"halted":0,"volume":12406705,"delay":0,"changeRate":0.0152,"floatShares":1121000000,"shares":1692000000,"eps":0.4312,"marketStatus":"交易中","change":0.14,"latestTime":"06-29 10:34:27","open":9.2,"high":9.43,"low":8.87,"amount":113000000,"amplitude":0.0606,"askPrice":9.38,"askSize":65,"bidPrice":9.37,"bidSize":70,"shortable":0,"etf":0,"ttmEps":0.4312,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1782703800000},"marketStatusCode":2,"adr":0,"adjPreClose":9.24,"symbolType":"stock","openAndCloseTimeList":[[1782696600000,1782703800000],[1782709200000,1782716400000]],"highLimit":10.16,"lowLimit":8.32,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1691677031,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":21.753247,"roe":"3.55%","epsLYR":0.47,"committee":-0.677396,"marketValue":15868000000,"turnoverRate":0.0111,"status":0,"floatMarketCap":10512000000},"requestUrl":"/m/hq/s/300146","defaultTab":"news","newsList":[{"id":"2646358940","title":"6月26日汤臣倍健创60日新低，体育LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358940","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358940?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:55","pubTimestamp":1782464144,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日汤臣倍健跌5.04%创60日新低，收盘报9.24元，换手率1.7%，成交量19.1万手，成交额1.8亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为富国基金的体育LOF。体育LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0114","161030","BK0146","300146","BK0028","BK0042","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644707780","title":"汤臣倍健(300146.SZ)拟5000万元投资原粒(北京)半导体 将持有其0.97%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2644707780","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644707780?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:54","pubTimestamp":1781780043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汤臣倍健(300146.SZ)发布公告，公司拟以自有资金5000万元投资原粒(北京)半导体技术有限公司，本次投资完成后，公司将持有其0.97%的股权。本次投资属于财务性投资，半导体领域是科技创新的重要方向，公司旨在通过投资布局建立对于前沿科技领域的认知窗口，分享科技企业成长带来的中长期价值提升，为公司及股东创造良好的财务回报，符合股东利益及国家创新驱动发展战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","BK0226","300146","BK0107","BK0028","BK0042","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638154221","title":"股市必读：汤臣倍健（300146）5月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638154221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638154221?lang=zh_cn&edition=full","pubTime":"2026-05-27 03:04","pubTimestamp":1779822254,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，汤臣倍健报收于9.77元，上涨0.31%，换手率0.92%，成交量10.36万手，成交额1.01亿元。董秘最新回复投资者： 投资者在抖音看到了公司关于轻络素的视频，请问公司的轻络素产品是否已经投产？公司轻络素相关的新功能申报及产品注册申请目前尚在审批中。上述非品牌代言合作，公司根据市场推广需求开展各类内容素材合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700002340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0042","BK0226","BK0114","BK0146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638330233","title":"股市必读：汤臣倍健（300146）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638330233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638330233?lang=zh_cn&edition=full","pubTime":"2026-05-25 02:47","pubTimestamp":1779648430,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，汤臣倍健报收于9.9元，下跌0.9%，换手率1.46%，成交量16.34万手，成交额1.62亿元。董秘最新回复投资者： 公司账上这么多现金有投资计划吗？公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。当日关注点来自交易信息汇总：5月22日主力资金净流出664.0万元，游资与散户资金呈净流入态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0226","BK0028","BK0114","300146","BK0107","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637182893","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637182893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637182893?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:54","pubTimestamp":1779443654,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：轻络素片审批进度是不是在4.27有状态变化？豆包说已通过正在等待行政审批？请给个具体的进度汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。感谢关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0042","BK0028","300146","BK0107","BK0146","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637871392","title":"5月22日汤臣倍健创60日新低，体育LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637871392","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637871392?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:40","pubTimestamp":1779439209,"startTime":"0","endTime":"0","summary":"证券之星消息，5月22日汤臣倍健创60日新低，收盘报9.9元，当日跌0.9%，换手率1.46%，成交量16.34万手，成交额1.62亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为富国基金的体育LOF。体育LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0146","BK0107","161030","BK0028","BK0114","300146","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637482098","title":"股市必读：汤臣倍健（300146）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637482098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637482098?lang=zh_cn&edition=full","pubTime":"2026-05-21 03:36","pubTimestamp":1779305774,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，汤臣倍健报收于10.04元，下跌1.08%，换手率0.77%，成交量8.65万手，成交额8693.79万元。董秘最新回复投资者： 建议公司成为张雪机车的赞助商，有利于提高公司知名度。公司2026年度经营目标指引请查阅2025年年度报告，具体业绩实现情况以公司定期报告为准。具体请以公司正式发布的产品上市信息为准。当日关注点来自交易信息汇总：5月20日主力资金净流出238.98万元，游资资金净流入611.68万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100004469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0226","BK0146","BK0042","BK0114","300146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636843764","title":"汤臣倍健：公司始终聚焦主业，致力于实现可持续、有质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2636843764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636843764?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:09","pubTimestamp":1779271757,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，梁总，当今科技，半导体大行其道，梁总有没有想过跨界科技，半导体，开启多元化发展？汤臣倍健回复：投资者您好！公司始终聚焦主业，致力于实现可持续、有质量发展，长期创造价值回报广大投资者。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0226","BK0042","BK0114","BK0107","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636083620","title":"股市必读：汤臣倍健（300146）5月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636083620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636083620?lang=zh_cn&edition=full","pubTime":"2026-05-19 00:59","pubTimestamp":1779123549,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，汤臣倍健报收于10.06元，下跌1.08%，换手率1.27%，成交量14.19万手，成交额1.43亿元。董秘最新回复投资者： 《药品试验数据保护实施办法》即将实施，请问公司的保健品实验数据是否同样适用于该办法？保健食品不适用上述法规。当日关注点来自交易信息汇总：5月18日主力资金净流出2250.4万元，散户资金净流入2393.96万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300146","BK0146","BK0226","BK0042","BK0114","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636291750","title":"汤臣倍健：保健食品不适用上述法规","url":"https://stock-news.laohu8.com/highlight/detail?id=2636291750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636291750?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:33","pubTimestamp":1779096787,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：《药品试验数据保护实施办法》即将实施，请问公司的保健品实验数据是否同样适用于该办法？汤臣倍健回复：投资者您好！保健食品不适用上述法规。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800026758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0107","300146","BK0028","BK0042","BK0146","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635702783","title":"汤臣倍健：公司目前未投资DeepSeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2635702783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635702783?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:00","pubTimestamp":1778835640,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否直接或间接投的投资了DeepSeek公司？公司后续是否考虑增加月之暗面公司的投资？汤臣倍健回复：投资者您好！公司目前未投资DeepSeek，具体情况请以公司公告为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500029899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634263649","title":"东吴证券：给予汤臣倍健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634263649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634263649?lang=zh_cn&edition=full","pubTime":"2026-05-12 11:57","pubTimestamp":1778558251,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司苏铖,邓洁近期对汤臣倍健进行研究并发布了研究报告《磨砺以须，倍道而进》，给予汤臣倍健买入评级。对应PE23、22、20x，考虑到公司C端基础佳，新渠道、新市场探索积极，我们认为当下估值仍具性价比，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级3家，增持评级5家，中性评级1家；过去90天内机构目标均价为12.35。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200018274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240071","title":"汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634240071?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:36","pubTimestamp":1778495773,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健05月11日在投资者关系平台上答复投资者关心的问题。请问公司的在研抗衰项目和上述项目比有哪些优势？公司始终重视抗衰老领域的科研探索与技术积累，持续跟踪国内外前沿科学动态，通过相关前瞻性基础研究及成果转化等，持续打造产品力和科技竞争力优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100028838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0042","BK0226","BK0114","BK0146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111078","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111078","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633111078?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:30","pubTimestamp":1778149820,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，轻络素的新功能技术审评进入行政批复了没有？对于这个研发11年的大单品，公司是否有做好了上市前期的所有准备？请如实回答，谢谢！汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700031701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0114","BK0226","300146","BK0042","BK0107","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633110873","title":"汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2633110873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633110873?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:21","pubTimestamp":1778149264,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司能否在抗衰老产品上培育利润增长点？汤臣倍健回复：投资者您好！公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累，持续跟踪国内外前沿科学动态。国家市场监督管理总局目前尚未将“抗衰老”单独列为可声称的保健功能，公司将在符合法规要求的框架下，为消费者提供高品质的健康选择。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700031464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0226","300146","BK0146","BK0114","BK0107","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630370526","title":"汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2630370526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630370526?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:18","pubTimestamp":1777371509,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月28日在投资者关系平台上答复投资者关心的问题。请勿用标准化话术搪塞汤臣倍健回复：投资者您好！公司业绩表现受外部消费环境、行业竞争格局、渠道格局变化及公司的主动调整等多重因素影响，公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略，围绕消费者需求持续优化产品组合，不断提升精细化管理能力，确保公司长期健康发展，回报广大投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0146","BK0226","BK0042","BK0028","BK0114","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870633","title":"汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870633","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870633?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:11","pubTimestamp":1777108313,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汤臣倍健披露，截至2026年3月31日公司股东户数为6.49万户，较2月28日增加319.0户，增幅为0.49%。在食品加工行业个股中，汤臣倍健股东户数高于行业平均水平，截至3月31日，食品加工行业平均股东户数为3.26万户。从股价来看，2026年2月28日至2026年3月31日，汤臣倍健区间跌幅为8.96%，在此期间股东户数增加319.0户，增幅为0.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0107","BK0028","BK0042","BK0146","300146","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629825196","title":"汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629825196","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629825196?lang=zh_cn&edition=full","pubTime":"2026-04-24 23:51","pubTimestamp":1777045896,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汤臣倍健(300146.SZ)发布2026年第一季度报告，该公司营业收入为18.69亿元，同比增长4.30%。归属于上市公司股东的净利润为4.02亿元，同比减少11.62%。归属于上市公司股东的扣除非经常性损益的净利润为3.75亿元，同比减少8.19%。基本每股收益为0.24元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629202425","title":"股市必读：汤臣倍健（300146）4月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2629202425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629202425?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:49","pubTimestamp":1776883783,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，汤臣倍健报收于10.66元，下跌0.56%，换手率0.86%，成交量9.59万手，成交额1.02亿元。董秘最新回复投资者： 尊敬的董秘你好：近期，益生菌减肥的效果被社会关注。公司旗下相关益生菌产品的保健功能以“调节肠道菌群、增强免疫力”为主。公司对自有益生菌菌株进行了多项体外、动物及人体临床试验研究，以发掘其调节糖脂代谢、体重控制、肠道屏障修复、降尿酸等多方面的功效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300005057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300146","BK0107","BK0146","BK0114","BK0042","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019522","title":"汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629019522?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:18","pubTimestamp":1776849485,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月22日在投资者关系平台上答复投资者关心的问题。上述新功能申报及产品注册申请的补充材料已提交，目前尚在审批中。公司业绩表现受外部消费环境、行业竞争格局、渠道格局变化及公司的主动调整等多重因素影响，公司将持续优化业务策略，发挥科研创新优势，不断打造与提升科技力、产品力、品牌力、渠道力、服务力等核心竞争力，以保持公司的市场领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200039601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0226","300146","BK0114","BK0146","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782700469910,"stockEarnings":[{"period":"1week","weight":-0.0591},{"period":"1month","weight":-0.0484},{"period":"3month","weight":-0.1226},{"period":"6month","weight":-0.2136},{"period":"1year","weight":-0.1413},{"period":"ytd","weight":-0.1985}],"compareEarnings":[{"period":"1week","weight":-0.0155},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.029},{"period":"6month","weight":0.016},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"汤臣倍健股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"64893人(较上一季度增加0.49%)","perCapita":"17269股","listingDate":"2010-12-15","address":"广东省珠海市金湾区三灶科技工业园星汉路19号","registeredCapital":"169167万元","survey":" 汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汤臣倍健,300146,汤臣倍健股票,汤臣倍健股票老虎,汤臣倍健股票老虎国际,汤臣倍健行情,汤臣倍健股票行情,汤臣倍健股价,汤臣倍健股市,汤臣倍健股票价格,汤臣倍健股票交易,汤臣倍健股票购买,汤臣倍健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}